Application of MicroRNA-433 in preparation of medicament for treating renal failure complicated hypertension, and medicament
A mir-433, high blood pressure technology, applied in gene therapy, drug combinations, pharmaceutical formulations, etc., can solve the problems of not producing effective results, promoting nephritis, impairing the anti-inflammatory properties of TGF-beta, and inhibiting renal fibrosis. the effect of
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0030] Embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings. It should be emphasized that the following description is only exemplary and not intended to limit the scope of the invention and its application.
[0031] In the embodiment of the present invention, it is preferable to transfect the shRNA plasmid inhibiting miR-433 into the kidney by ultrasonic microvesicle plasmid transfection technology, so as to down-regulate the expression of miR-433 in kidney cells. The good effect of miR-433 in the treatment of chronic hypertensive kidney disease can be detected. Since the microRNA regulated by TGF-beta plays an important role in the process of TGF-beta-induced fibrosis, we can specifically target TGF-beta downstream microRNA to inhibit the downstream pathway of TGF-beta, thereby controlling TGF-beta beta-induced fibrosis without compromising the anti-inflammatory properties of TGF-beta would be a better option f...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


